Company shares last traded at $23.63 which is just over the 50 day moving average of $22.40 and which is marginally higher than the 200 day moving average of $17.00. The 50 day moving average was up $1.23 or +5.48% and the 200 day average moved up $6.63. Trading volume for Axovant Sciences Ltd. was 0 on Wednesday. Volume was down 0.00% under the stocks average daily volume.
There has been some buying insider activity on Axovant Sciences Ltd. (NYSE:AXON) recently. W. Anthony Vernon, Director bought $999,992 worth of shares at an average price of $18.54 on Mon the 17th. That brings the Director’s holdings to $999,992 as reported to the SEC. Kathryn E. Falberg, Director disclosed the purchase of 53,937 shares of AXON stock. The shares were purchased at an average price of $18.54. The Director now owns $999,992 of the stock according to the SEC filing.
David Hung, Principal Executive Officer purchased $10,000,013 worth of shares at an average price of $18.54 on April 17th. The Principal Executive Officer now owns $10,000,013 of the stock as recorded in a recent Form 4 SEC filing.
The following firms have also recently changed their position in AXON. Creative Planning cut its position by selling 2,937 shares a decrease of 97.9%. Creative Planning now controls 63 shares valued at $1,000. The value of the position overall is down by 97.3%. As of quarter end Morgan Stanley had acquired 427 shares growing its position 18.2%. The value of the investment in Axovant Sciences Ltd. increased from $29,000 to $42,000 a change of 44.8% quarter over quarter.
As of the end of the quarter Goldman Sachs Group Inc had sold a total of 85,400 shares trimming its holdings by 46.1%. The value in dollars went from $2,303,000 to $1,494,000 decreasing 35.1% quarter to quarter. Janus Capital Management LLC downsized its ownership by shedding 180,233 shares a decrease of 3.9% in the quarter. Janus Capital Management LLC claims 4,498,991 shares worth $67,213,000. The total value of its holdings increased 15.6%.
On December 6 analysts at Oppenheimer issued its first research report on the stock giving it an initial rating of “Outperform”. On June 7, 2016 Leerink Swann initiated coverage by announcing an initial rating of “Outperform” and a price target of $22.00.
Equity analyst H.C. Wainwright added the stock to its research portfolio with an initial rating of “Buy” and price target of $35.00. Piper Jaffray started covering the stock setting a rating of “Overweight”.
JMP Securities began coverage with a rating of “Outperform” and projecting a price target of $36.00. On July 13, 2015 Baird added AXON to its research portfolio with an initial rating of “Outperform” and establishing a price target of $29.00.
The company is trading up by 6.97 percent from yesterday’s close. In the latest earnings report the EPS was $-1.83 and is projected to be $-2.20 for the current year with 107,392,000 shares outstanding. Next quarter’s EPS is expected be $-0.56 and the next full year EPS is projected to be $-2.68.
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., launched on October 31, 2014, is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders..